

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.

*This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the “**U.S. Securities Act**”), and may not be offered or sold in the United States unless registered under the U.S. Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration under the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.*



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

EXTENSION OF COMPLETION OF SUBSCRIPTION OF SHARES UNDER TOP-UP PLACING AND SUBSCRIPTION

Reference is made to the announcement of the Company dated 5 June 2018 in relation to the Vendor Placing, the Subscription and the Wang Placing (the “**Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, completion of the Subscription was expected to take place on 12 June 2018. As at the publication of this announcement, the Listing Committee of the Stock Exchange granting the listing of and permission to deal in the Subscription Shares being one of the conditions of the Subscription has not been fulfilled.

Under such circumstances and subject to the receiving of the approval from the Listing Committee granting the listing of and permission to deal in the Subscription Shares, the completion of the Subscription is currently expected to take place on or before 15 June 2018.

The Company will continue to make timely disclosure of any relevant information pursuant to the relevant requirements of the Listing Rules.

As completion of the Subscription is subject to the satisfaction of the conditions precedent of the Subscription and may or may not materialize as contemplated or at all, Shareholders and investors are reminded to exercise caution when dealing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
Dr. Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 13 June 2018

As at the date of this announcement, our executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye, and Mr. MENG Jiange; our non-executive Directors are Dr. WANG Luquan and Mr. PAN Yuexin; and our independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian, and Ms. ZHANG Min.

* *For identification purposes only*